# NCT04619004 (NCT04619004)

> HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04619004
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
- Interventions: Patritumab Deruxtecan (Fixed dose); Patritumab Deruxtecan (Up-Titration)
- Enrollment: 277
- Primary outcome: Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)

## Commentary we found

- X threads: 24
- YouTube: 20
- Podcasts: 20

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct04619004

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04619004", "email": "<work email>"}; the inbox owner confirms by the emailed link.